The comparative study of quality of life and toxicities in patients with chronic myeloid leukemia during imatinib therapy vs. nilotinib therapy.

Trial Profile

The comparative study of quality of life and toxicities in patients with chronic myeloid leukemia during imatinib therapy vs. nilotinib therapy.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 May 2012

At a glance

  • Drugs Imatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date (May 2021) added as reported by Chinese Clinical Trial Register.
    • 14 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top